Company intelligence / Profile preview

Jiangsu Bioda Life Science

Nantong, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Jiangsu Bioda Life Science is the first company in China to mass-produce artificial blood vessels. Its flagship product, the VASOLINE® vascular graft, received Class III medical device approval from China's NMPA in November 2022. The company also produces hernia mesh and suture materials. Mass production began in early 2023, aiming for a domestic market share of at least 50% for artificial blood vessels.

Therapeutic areas: Cardiovascular
Modalities: DeviceBiomaterial-based medical device
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Jiangsu Bioda Life Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Bioda Life Science.

Explore the full profile